Drawing for BLACKPILL

USPTO serial 99975192

BLACKPILL

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
—
Law office
TMEG LAW OFFICE 101

What this means

Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies. Wait for assignment and the first examiner action. Monitor TSDR monthly for status changes to 638 (assigned) or an office action.

Status 630: Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies.

Need help with BLACKPILL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Probiotic supplements; Mineral supplements; Herbal supplements; Vitamin supplements; Dietary supplements; Protein supplements; Enzyme food supplements; Dietary food supplements; Health food supplements; Nutritional supplementsACTIVEJan 6, 2026

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 18, 2026DPCCDIVISIONAL PROCESSING COMPLETE—
Jan 14, 2026AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jan 14, 2026ALIEASSIGNED TO LIE—
Jan 6, 2026DRRRDIVISIONAL REQUEST RECEIVED—
Jan 6, 2026EAAUTEAS AMENDMENT OF USE RECEIVED—
Jan 6, 2026ERTDTEAS REQUEST TO DIVIDE RECEIVED—
Dec 29, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 28, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance